for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

Latest Trade

64.92EUR

Change

-0.30(-0.46%)

Volume

588,029

Today's Range

64.51

 - 

65.23

52 Week Range

52.02

 - 

79.47

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
65.22
Open
65.18
Volume
588,029
3M AVG Volume
70.02
Today's High
65.23
Today's Low
64.51
52 Week High
79.47
52 Week Low
52.02
Shares Out (MIL)
932.56
Market Cap (MIL)
60,821.31
Forward P/E
9.94
Dividend (Yield %)
4.29

Next Event

Q3 2019 Bayer AG Earnings Release

Latest Developments

More

Sensyne Health Says Expanded Collaboration Agreement With Bayer

Bayer And Arvinas Unveil Targeted Protein Degradation Joint Venture

Bayer Wins First EU Approval For High-Precision Cancer Drug

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bayer AG

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

Industry

Major Drugs

Contact Info

Kaiser-Wilhelm-Allee 1

+49.214.301

https://www.bayer.de/

Executive Leadership

Werner Wenning

Independent Chairman of the Supervisory Board

Werner Baumann

Chairman of the Management Board, Chief Executive Officer

Oliver Zuehlke

Independent Vice Chairman of the Supervisory Board, Employee Representative

Wolfgang U. Nickl

Chief Financial Officer, Member of the Management Board

Hartmut Klusik

Member of the Management Board, Director of Human Resources, Technology & Sustainability, Labor Director

Key Stats

2.39 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

46.8K

2017

35.0K

2018

39.6K

2019(E)

46.1K
EPS (EUR)

2016

7.204

2017

6.633

2018

5.940

2019(E)

6.563
Price To Earnings (TTM)
108.70
Price To Sales (TTM)
1.34
Price To Book (MRQ)
1.36
Price To Cash Flow (TTM)
10.94
Total Debt To Equity (MRQ)
96.77
LT Debt To Equity (MRQ)
82.01
Return on Investment (TTM)
0.56
Return on Equity (TTM)
0.45

Latest News

Latest News

German stocks - Factors to watch on Oct. 14

The following are some of the factors that may move German stocks on Monday:

Australian farmer brings legal action vs Bayer over weedkiller: report

An Australian farmer has launched a legal action against Bayer AG's agricultural chemicals unit Monsanto after being diagnosed with a type of cancer he says was caused by its weedkiller, a lawyer for the man said on Friday.

Australian farmer launches legal action against Bayer over weedkiller-report

An Australian farmer has launched a legal case against Bayer AG's agricultural chemicals unit Monsanto after being diagnosed with a type of leukaemia, the Australian Broadcasting Commission reported on Thursday.

Bayer says Oct. U.S. glyphosate trial delayed until further notice

(This October 6 story has been refilled to correct "until February" to "until further notice" in headline and "new court date" to "court status conference" in paragraphs 1 & 6)

CORRECTED-UPDATE 1-European shares muted as gains in defensives outweigh nerves on trade, Brexit

European shares were little changed in choppy trade on Monday, after their steepest weekly loss in two months, as bids in defensive shares outweighed nervousness ahead of crucial U.S.-China trade talks and Brexit negotiations.

Bayer says another U.S. glyphosate trial is delayed

A pending U.S. lawsuit over claims related to Bayer's glyphosate-based herbicide Roundup has been delayed, the company said on Sunday.

Bayer to spend over 25 billion euros in crop science R&D over 10 years

German drugmaker Bayer <BAYGn.DE> on Tuesday said it is to spend more than 25 billion euros ($27.22 billion) on research and development at its agriculture unit over the next 10 years.

Brazil grain growers wary of dicamba as Bayer launches new GM soy seed

A genetically modified soy seed technology from Germany's Bayer set to launch soon in Brazil has sparked concern from some farmers who worry that other crops could be impacted by dicamba, a herbicide the biotech product is designed to tolerate.

Brazil grain growers wary of dicamba as Bayer pushes new soy seed

Brazilian farmers are wary of the imminent introduction of a new genetically modified soy seed technology because of the risks associated with dicamba, a herbicide the biotech product is designed to tolerate.

UPDATE 1-Bayer to reduce size of management board to five

Bayer management board members Hartmut Klusik and Kemal Malik will leave at the end of the year without a replacement, as the German drugmaker reduces its board to five seats to cut costs.

Bayer to reduce size of management board to five

Bayer said on Tuesday that management board members Hartmut Klusik and Kemal Malik would leave the company at the end of the year without a replacement, reducing the German drugmaker's board to five seats. (Reporting by Ludwig Burger Editing by Tassilo Hummel)

UPDATE 2-Brazil judge orders Bayer to deposit $69 mln in soy patent dispute

A Brazilian judge has ordered Germany's Bayer to deposit an additional 286 million reais ($69.4 million) in an escrow account due to a patent dispute with local soybean farmers, according to a court decision seen by Reuters.

Brazil judge orders Bayer to deposit $69 mln in soy patent dispute

A Brazilian judge has ordered Germany's Bayer to deposit an additional 286 million reais ($69.4 million) in an escrow account due to a patent dispute with local soybean farmers, according to a court decision seen by Reuters.

Bayer hires former J&J executive for more pharma deals

Bayer <BAYGn.DE> said it hired Johnson & Johnson <JNJ.N> executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline.

What are the obstacles to Bayer settling Roundup lawsuits?

Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health <ELAN.N> agreed to buy Bayer's <BAYGn.DE> veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.

Elanco to buy Bayer's animal health unit for $7.6 billion

Elanco Animal Health Inc said on Tuesday it would buy Bayer AG's animal health unit in a cash and stock deal valued at $7.6 billion, a move that would create the second largest animal health business and expand Elanco's reach in the pet e-commerce space.

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

Bayer mediator dismisses report of $8 billion Roundup settlement

Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11% higher.

Bayer has not proposed paying $8 billion to settle U.S. Roundup claims: mediator

Bayer AG has not proposed paying $8 billion to settle all U.S. claims related to the Roundup herbicide, mediator Ken Feinberg said in an email on Friday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up